Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection

Public Health Genomics

Volumn 17, Issue , 2014, Pages 306-319

  Bock, Jonathan A ^a   Fairley, Kimberly J ^b   Smith, Robert E ^b   Maeng, Daniel D ^b   Pitcavage, James M ^b   Inverso, Nicholas A ^b   Williams, Marc S ^b  

^a WEIS CENTER FOR RESEARCH   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Decision tree; Hepatitis C virus; IL28 ; Markov modeling; Telaprevir

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HIDDEN MARKOV MODEL; HUMAN; OUTCOME ASSESSMENT; TREATMENT RESPONSE; ADULT; AGED; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; FEMALE; GENETICS; HEALTH CARE QUALITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84920192891     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000365939     Document Type: Article

References (25)

1. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW: Hepatitis C virus testing of persons born during 1945 to 1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157: 817-822.
2. McCombs JS, Yuan Y, Shin J, Saab S: Economic burden associated with patients diagnosed with hepatitis C. Clin Ther 2011; 33: 1268-1280.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S: Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
6. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T: Combined effects of different interleukin- 28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-1710.
7. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T: Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
8. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
9. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
10. Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H: IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
11. Lin C, Hanzelka BL, Müh U, Kovari L, Bartels DJ, Tigges AM, Miller J, Rao BG, Kwong AD: Telaprevir (VX-950) is a potent inhibitor of HCV NS3-4A proteases derived from genotype non-1 HCV infected patients. J Hepatol 2007; 46(suppl 1):S8.
12. Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M: Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889.e1.
13. Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxi A; WEF Study Group: Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-860.
14. Lindh M, Lagging M, Färkkilä M, Langeland N, Mørch K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K: Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752.
15. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group: Cost effectiveness of peginterferon alpha- 2b plus ribavirin versus interferon alpha- 2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432.
16. Cardinal Health. Pharmaceutical Distribution; Entelligence Version 6.0.
17. United States Department of Veterans Affairs: Hepatitis C, Antiviral TX Strategy, Genotype 2-3. 2006.
18. Centers for Medicare and Medicaid Services, American Medical Association: Clinical Diagnostic Laboratory Fee Schedule 2012.
19. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J: Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123-128.
20. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group: Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501.
21. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ: Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
22. Arias E: United States Life Tables 2008. NVSS 2012; 61.
23. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB: Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005; 8: 3-9.
24. Frei P, Leucht AK, Held U, Kofmehl R, Manser CN, Schmitt J, Mertens J, Rau M, Baur K, Gerlach T, Negro F, Heim M, Moradpour D, Cerny A, Dufour JF, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group: Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-alpha and ribavirin in chronic hepatitis C virus patients. Liver Int 2014; 34: 551-557.
25. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J: Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 1490-1496.